Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (AVDL – Research Report), Masimo (MASI – Research Report) and Seres Therapeutics (MCRB – Research Report).
Avadel Pharmaceuticals (AVDL)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Avadel Pharmaceuticals today and set a price target of $13.00. The company’s shares closed last Monday at $11.73, close to its 52-week high of $12.21.
According to TipRanks.com, Amsellem has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Avadel Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $16.07, implying a 52.9% upside from current levels. In a report issued on April 17, Needham also maintained a Buy rating on the stock with a $11.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Masimo (MASI)
In a report released today, Jason Bednar from Piper Sandler assigned a Hold rating to Masimo, with a price target of $150.00. The company’s shares closed last Monday at $189.06, close to its 52-week high of $198.00.
According to TipRanks.com, Bednar is a 1-star analyst with an average return of
Masimo has an analyst consensus of Strong Buy, with a price target consensus of $188.67.
Seres Therapeutics (MCRB)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Seres Therapeutics, with a price target of $13.00. The company’s shares closed last Monday at $4.87.
According to TipRanks.com, Tenthoff is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seres Therapeutics with a $10.50 average price target, implying an 116.0% upside from current levels. In a report issued on April 27, Jefferies also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVDL:
- Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
- Avadel Pharmaceuticals management to meet with Needham
- Largest borrow rate increases among liquid names
- Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
